Gilead still hasn't made up its mind about Arcus' drugs, but there's a top exec at the biotech it definitely wants
Gilead made clear it’s in for the long I/O game when it outlined a $2 billion deal with Arcus — including $375 million paid upfront — that would span a full decade. One year in, it’s tapping a trusty steward to manage that alliance.
Bill Grossman, Arcus’ CMO of two years, will be taking up a new role as Gilead’s SVP of oncology clinical research. There, he is tasked with overseeing the clinical-stage oncology portfolio — including the four Arcus programs for which Gilead has claimed opt-in rights.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
